Coming Soon

Tirzepatide is on the waitlist. Retatrutide is currently our only active protocol. Get notified when Tirzepatide launches →

Weight Loss · The proven one

Tirzepatide.
The same molecule. A quarter of the price.

Average 21% body-weight loss in 72 weeks. The molecule US clinics charge $1,200/month for. Compounded in Medellín. Physician-supervised.

$480.000 COP / 10mg vial · launch pricing
Join the Waitlist
21%

Average body-weight loss at 72 weeks (SURMOUNT-1)

2

Receptor agonist (GLP-1 + GIP)

$1.2K

What US wellness clinics charge per month. You'll pay $120.

The weight-loss protocol that actually works.

Tirzepatide is the active ingredient in Mounjaro and Zepbound. It activates two metabolic receptors (GLP-1 and GIP) that control hunger, satiety, glucose, and fat metabolism. The SURMOUNT-1 trial (NEJM, 2022) showed an average 20.9% body-weight loss at the highest dose over 72 weeks — the strongest weight-loss result for any FDA-approved medication at the time of publication.

In the US, getting it costs $1,000–$1,500/month at a compounding pharmacy or $1,400/month for branded Mounjaro. Our magistral pharmacy partner in Medellín delivers the identical molecule at one-quarter the price, with a real physician designing your protocol.

Why this is the protocol most of our patients start with.

This is for you if

You have 20+ pounds to lose. You want a proven molecule with years of clinical data. You're ready to titrate up slowly. You want a physician designing your protocol, not a Telegram channel.

This is NOT for you if

You have MTC or MEN2 history. Active pancreatitis or gallbladder issues. Pregnancy or breastfeeding. Severe gastroparesis. Our intake screens for all of these.

Your transformation, week by week.

Drawn from the SURMOUNT-1 published data. Real outcomes vary; our physician calibrates titration to your tolerance and goals.

Week 1–4

Appetite shifts.

Cravings quiet down. Portion sizes drop without willpower. Mild nausea common in week 1.

Week 8–12

5–10% body weight gone.

Energy stable. Clothes loose. Metabolic markers improving.

Week 24–36

15%+ body weight gone.

Body composition transformation visible. Long-term habits rebuilt around lower appetite.

Week 72

21% mean weight loss.

SURMOUNT-1 endpoint at highest dose. Maintenance protocol designed during taper.

$120 here. $1,200 there.
Same molecule.

It's not magic. It's regulatory and economic structure. US compounding pharmacies operate under FDA enforcement risk that adds 60–70% to their cost basis. Colombian magistral pharmacies under Decreto 2200/2005 do the same work with different overhead. Our physician oversight is equivalent. Your protocol is identical.

Side effects — honestly.

Most are GI and dose-related. The SURMOUNT trials report them in detail. Our physician walks you through every one during intake and during dose escalations.

Common

Nausea · Diarrhea · Constipation · Decreased appetite (the point) · Burping · Fatigue in early titration

Less common, take seriously

Pancreatitis (rare) · Gallbladder disease · Severe gastroparesis · Allergic reactions · Hypoglycemia if combined with insulin

When to call us immediately

Severe persistent abdominal pain · Vomiting that won't stop · Signs of allergic reaction · Severe hypoglycemia symptoms. WhatsApp the medical team — 24-hour line for active patients.

Simple pricing.

Everything included. Physician intake. Compounded vial. Cold-chain delivery. Monthly check-in. WhatsApp access.

Starter (Titration)

$480.000 COP / 4 weeks

10mg vial · 2.5mg–5mg starting dose · MD intake · Shipping (launch pricing)

Therapeutic

$880.000 COP / 4 weeks

15mg vial · 7.5–15mg therapeutic dose · MD check-in · Priority WhatsApp (launch pricing)

Join the Waitlist

Tirzepatide is dispensed via magistral compounding under individual physician prescription in compliance with Colombian regulatory frameworks (Decreto 2200/2005, Resolución 1403/2007). Branded Mounjaro and Zepbound are Eli Lilly products and unrelated to this compounded preparation. Cited weight-loss percentages reference Jastreboff et al., 2022 (NEJM, SURMOUNT-1); individual results vary. Not for use in pregnancy, breastfeeding, MTC/MEN2 family history, active pancreatitis, or severe gastroparesis. Discuss your medical history with our physician during intake.